{"id":"NCT02483078","sponsor":"CytoDyn, Inc.","briefTitle":"Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140","officialTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-10","primaryCompletion":"2018-02","completion":"2018-07","firstPosted":"2015-06-26","resultsPosted":"2022-11-03","lastUpdate":"2022-11-03"},"enrollment":52,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["HIV"],"interventions":[{"type":"DRUG","name":"PRO 140","otherNames":["PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Optimized Background Regimen","otherNames":["Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history."]}],"arms":[{"label":"PRO 140","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 2b/3, multi-center, two part study, designed to evaluate the efficacy, safety, and tolerability of PRO 140 in conjunction with existing ART (failing regimen) for one week and Optimized Background Therapy (OBT) for 24 weeks respectively. Study population includes treatment-experienced HIV-infected patients with CCR5-tropic virus who demonstrates evidence of HIV-1 replication despite ongoing antiretroviral therapy with documented genotypic or phenotypic resistance to ART drugs within three drug classes (or within two or more drug classes with limited treatment options).The options may be limited as a result of drug antiviral class cross-resistance or documented treatment intolerance.","primaryOutcome":{"measure":"Proportion of Participants With â‰¥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period","timeFrame":"From baseline visit to week 1 visit","effectByArm":[{"arm":"PRO 140","deltaMin":0.64,"sd":null},{"arm":"Placebo","deltaMin":0.23,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":".0032"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["39972543"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Injection site haemorrhage","Diarrhoea","Arthralgia","Fatigue","Back pain"]}}